
Prisma Imaging
OperatingPrisma Imaging, Inc.
Healthcare · Alachua, FL · Founded 2016
Market a novel system that is capable of providing digital radiographic & ct imaging of a horse
Financials
FY2020–FY2022 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Fundraising history
Team
11 people
Brian serves as chief financial officer for Prisma and is a seasoned healthcare administrator bringing 25 years of experience within the healthcare sector including leadership roles in financial management, strategic development, and healthcare operations. His experience includes 20 years working as a healthcare administrator in the Atlanta healthcare market including positions with Emory University System of Healthcare, Saint Joseph's Health System, and Hospital Corporation of America (HCA) where he worked to develop some of the most successful physician-integration strategies in the Atlanta market. Brian provides a broad range of experience in health services delivery having worked within both hospital and physician management settings, including for profit/not-for-profit, and academic medical center environments. Brian serves as adjunct program faculty for the University of Florida’s Master of Health Administration program teaching healthcare financial management. Brian received an MBA/MHS Degree from the Warrington College of Business at the University of Florida, where he also earned a certificate degree in Entrepreneurship. He holds a BS in Communications, also from the University of Florida.

Michael has over 30 years of entrepreneurial and institutional experience. From 1992 until 2001, he worked for Ronald Perelman’s holding company, MacAndrews and Forbes, Inc., where he worked in a variety of capacities at the M&F companies. In 2002, he started a company, in the housewares industry that he built and successfully divested in 2012. After selling his company, Michael started Prisma Imaging in 2016. His motivation to start Prisma was to develop a solution that addressed the deficiencies that exist in equine imaging, his desire to create new beneficial technology, and his attraction to the contagious passion that exists within the equestrian community. Michael is committed to Prisma for the long-term, beyond the equine market and into the next phase of potential expanded industries that will become viable as Prisma’s technology advances. In addition to recognizing the merits of developing a ground-breaking, highly beneficial diagnostic technology, Michael is equally committed to supporting the humane treatment of animals in all categories, including our beloved pets, animals that live in captivity (in zoos and nature habitats), and in our food chain. Michael received his BA from Vanderbilt University and his MBA from Fordham.

Dr. Chris Mitchell has more than 25 years of hands-on and leadership experience in the design, development, and characterization of innovative x ray-based imaging systems for medical and industrial applications. Before joining Triple Ring Technologies, Dr. Mitchell served in a variety of positions at Alara, Inc., including VP of R&D and Chief Scientific Officer. While there, he led the development of a patented, award-winning bone densitometer, and several computed radiography-based imaging systems for medical, industrial, and veterinary applications. Prior to Alara, Dr. Mitchell served as Manager, Imaging Technologies, at ARACOR, where he led the development of a number of innovative imaging systems, including high-performance digital radiography, and cone-beam computed tomography for high resolution bone imaging and reverse engineering applications. Chris received his B.A. in applied mathematics from Weber State University, and MS (bioengineering) and Ph.D. (electrical engineering) from the University of Utah. He holds 3 patents in the fields of bone densitometry and computed radiography and has authored or co-authored numerous presentations and journal articles. He is a member of the American Association of Physicists in Medicine (AAPM).

Dr.Christopher Ellenor has experience building experimental systems comprising diverse technical elements. He has great experience on working on laser cooling, imaging and optical design, magnetic trapping of atoms, coil design and ultra-high vacuum (UHV) systems, MRI systems, with a focus on RF safety, as well as embedded and wireless electronics for sensing of patient motion and RF current.

David Scalzo is the Founder and Managing Partner for Kirenaga Partners. David co-founded the fintech company AdvisorEngine, served as its first CFO and sat on the Board of Directors until its sale to FranklinTempleton. In addition, he has extensive experience initiating, growing and managing businesses through various roles at Credit Suisse, Citadel, Bear Stearns, and Precision Plating Company. David serves on the Board for the Northwestern University Wildcat Athletic Venture Enterprise (NU/WAVE) investment fund, as well as numerous former and current portfolio companies. David graduated with a BS in Mechanical Engineering from Northwestern University, a Masters in Manufacturing Engineering from the Illinois Institute of Technology, a Masters in Engineering Management from Northwestern University, and a Masters in Business Administration from the Kellogg School of Management at Northwestern University.

Dr. Joe Heanue has significant leadership experience in device and instrumentation research & development within interdisciplinary environments. He previously served as Vice President of Engineering at NexRay and at Signature Bioscience. At NexRay, Joe led the development of a low-dose x-ray imaging system for interventional cardiology. At Signature, he headed a group that delivered prototype RF and microwave spectroscopy instruments to a major instrument partner; the first of these instruments was launched in 2005 by MDS Sciex. Joe’s extensive research and development experience includes the analysis and design of complex systems, x-ray and gamma-ray detector development, low-noise analog electronics, data-acquisition systems, signal and image processing, high-speed data-processing architectures, and thin-films failure analysis. Joe holds patents for detector and image processing, spectroscopy, and a patent for medical system imaging architecture that is licensed to a major medical equipment manufacturer. He received a BS in Physics from the Massachusetts Institute of Technology and earned his Ph.D. in Electrical Engineering and Computer Science from the University of California at Berkeley. Joe was a postdoctoral researcher at Xerox PARC, and he has completed the Stanford University Executive Program for Growing Companies.

Dr. Sheetal Patel began her career as a board certified Radiologist, earning her medical degree from University of Miami School of Medicine and going on to complete a residency in Radiology with University of South Florida in Tampa. She furthered her training with a fellowship in Musculoskeletal Radiology, a subspecialty which focuses on sports and orthopedic imaging (including bone and soft tissue tumors). After completing her residency and fellowship she worked with one of the top Radiology groups in Tampa, FL for 9 years. In 2014, while still practicing radiology, Dr. Patel completed her MBA at University of South Florida, finishing at the top of her class. Soon after earning her MBA she became more actively involved in various business endeavors. Gradually over the course of the next 2-3 years, she transitioned fully into a business role and away from practicing medicine, leading to her current role as COO of the Patel Family Office. As COO of the Patel Family Office she coordinates operations and investment management across all portfolios. In addition, she actively manages the family’s real estate portfolio consisting of just under $1B in assets across the hospitality, commercial real estate, and development sectors. Additionally, Dr. Patel is involved with various non-profit and charitable endeavors in the medical and education arenas both within and outside of the Patel Family Foundation which has projects both in the US and abroad. Locally, she also supports the Tampa Bay area as Vice President and board member of The Charity Polo Classic, an organization whose mission is “making a difference by collaborating with local charities to build a better Tampa Bay”.

Dr.Tobias Funk has years of experience in the development of instrumentation for science and medicine. Tobias is an experimental solid-state physicist by training and has focused on utilization of ionizing radiation throughout his career. He developed synchrotron instrumentation for spectroscopy on proteins and ultra-low temperature equipment for nuclear solid-state physics. He has authored over 20 peer-reviewed publications and has over 10 granted and pending patents.

Hailey’s area of expertise lies at the interface of bioinstrumentation and data science. Her experience is in a broad range of bioinstrumentation including magnetic resonance imaging development, point of care device design and testing, neutron generator and linear accelerators for use in healthcare, and development of data processing and machine learning technologies. She has been involved in various stages of the product development pipeline, from design verification to manufacturing quality control.
Show 2 more peopleShow fewer

Russell Ford has over 18 years experience in the design and development of innovative medical products and manufacturing processes. Russell’s expertise includes wearable and implantable devices, surgical equipment and complex drug delivery devices. Russell’s has a long history of senior level positions at Zosano Pharma, Abbott Medical Optics, Boston Scientific Neurovascular, and Cygnus Therapeutics. His expertise focuses on applications that include transdermal drug delivery, continuous glucose monitoring, minimally-invasive devices for cataract and laser surgery, as well as neuro-endovascular applications. Russell project management expertise ranges from early stage development through V&V, DFM, high volume scale-up, and commercial launch. Experience also includes development of system level, design, characterization, test method development, materials selection, supplier development, manufacturing process design, and quality systems.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 4 annual reports (FY2022–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.